Novo Nordisk

Novo Nordisk to create the world's first all-diabetes professional cycling team

Novo NordiskNovo Nordisk announced a unique partnership to form Team Novo Nordisk, a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team.

Team Novo Nordisk will use life experiences and competitiveness to motivate people affected by diabetes. Throughout 2013, these athletes will compete in more than 500 sporting competitions around the world. The men's pro-cycling team will compete in races such as the USA Pro Cycling Challenge, the Tour of Britain and the Paris-Tours, with the ultimate goal of joining the Tour de France.

"As part of our long-standing Changing Diabetes® programme, this partnership provides a tremendous opportunity to raise awareness, and educate, empower and inspire people with diabetes," says Jakob Riis, senior vice president, Global Marketing and Global Medical Affairs, Novo Nordisk. "This is yet another way Novo Nordisk is striving to create more opportunities to live well with diabetes."

Phil Southerland founded what was known as 'Team Type 1' in 2005 and included riders and athletes with and without diabetes until this year. The new Team Novo Nordisk will only comprise of athletes who have diabetes and will continue to grow the team mission "to instil hope and inspiration for people around the world affected by diabetes."

"As Team Novo Nordisk we want to show the world what is possible with great diabetes control. Between us, Team Novo Nordisk has over 1,000 diagnosed years of diabetes with no complications and we stand for what life with diabetes can be like," Southerland says. "Exercise is that billion dollar drug that nobody ever gets prescribed, and in my experience is the best of them all. With appropriate diet, exercise, treatment and technology, anyone with diabetes can achieve their dreams."

About Diabetes
Today, 371 million people are living with diabetes.(1) Changing Diabetes® is Novo Nordisk's global commitment to improve conditions for the millions of people who live with diabetes around the world today, and those who are at risk of developing diabetes tomorrow. It is a global advocacy and partner platform which advocates for the prevention and early detection of diabetes, as well as improved treatment, care and health outcomes.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

1. International Diabetes Federation. IDF Diabetes Atlas, 5th Edition, 2012 Update. Brussels, Belgium: International Diabetes Federation.

Most Popular Now

A new method cuts the cost of drug-…

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu...

Read more

Six leading scientists to receive p…

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo...

Read more

Pfizer announces publication of new…

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po...

Read more

Why is breast cancer common but hea…

Malignant cancers strike certain organs, such as the colon or breast, more often than others. In an Opinion publishing August 9 in Trends in Cancer, researchers propose t...

Read more

Legions of nanorobots target cancer…

Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research. They have develope...

Read more

Amgen and Advaxis enter global canc…

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical inve...

Read more

Researchers develop safer opioid pa…

An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni...

Read more

Natural compound from a deep-water …

Scientists at Florida Atlantic University's Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale's coast contains ...

Read more

Esketamine receives Breakthrough Th…

Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has gran...

Read more

Intestinal flora effects drug respo…

Intestinal flora has multiple influences on human health, but researchers have revealed that it is also likely to have an effect on the body's response to drugs. Recent r...

Read more

Outdated assessment of treatment re…

Tumor shrinkage is not the only measure of a successful anti-cancer therapy. A University of Colorado Cancer Center article published in the journal Frontiers in Oncology...

Read more

Bayer and CRISPR Therapeutics joint…

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016